ArticleClinical oral investigations2025
A retrospective, cross-sectional analysis of the dental status and needs of patients taking vascular endothelial growth factor (VEGF) antagonists.
Article in Clinical oral investigations, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThere is growing literature related to the dental effects of biologic agents. However, little research has evaluated the dental needs of these patients and limited data is available on patients taking vascular endothelial growth factor (VEGF) antagonists. MATERIALS AND
methodsThis retrospective cross-sectional study analyzed patients taking VEGF antagonists and their respective dental treatments from 2017 to 2023. Patient demographics, decayed, missing, and filled tooth (DMFT) status, and treatment details were recorded and evaluated descriptively. DMFT from this population was compared to patients taking other biologic agents using t-tests.
resultsTwenty-three patients taking VEGF antagonists received dental treatment. Periodontal treatments were the most common (n = 18, 78%), followed by restorative treatments (n = 17, 74%). DMFT data for patients taking VEGF antagonists were not significantly different than values for patients taking other biologic agents, except for patients taking TNF-α Inhibitors, who had significantly fewer missing teeth than patients taking VEGF antagonists (3.88 vs. 8.10, p = 0.01).
conclusionsThe necessity of dental treatment in patients taking VEGF Antagonists is still unknown. Periodontal and restorative treatments were the most common modalities with no complications observed from treatment. While preventive periodontal treatment is routinely recommended, high usage of targeted periodontal and restorative treatments is seen in this population. CLINICAL RELEVANCE: Minimal evidence exists to date on the delivery of and need for routine dental treatment among patients taking VEGF antagonists. This paper presents a first estimate of dental needs in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.